Ampio Pharmaceuticals, Inc. (AMPE): Price and Financial Metrics
GET POWR RATINGS... FREE!
AMPE Stock Price Chart Interactive Chart >
AMPE Price/Volume Stats
| Current price | $0.17 | 52-week high | $1.98 |
| Prev. close | $0.17 | 52-week low | $0.15 |
| Day low | $0.16 | Volume | 4,394,900 |
| Day high | $0.17 | Avg. volume | 2,465,593 |
| 50-day MA | $0.32 | Dividend yield | N/A |
| 200-day MA | $0.88 | Market Cap | 38.85M |
Ampio Pharmaceuticals, Inc. (AMPE) Company Bio
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. It is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. The company's product pipeline includes Ampion, which is in phase III clinical trial, is an intra-articular injection for the treatment of osteoarthritis of the knee. Ampio Pharmaceuticals, Inc. has collaborative research agreements to explore new clinical indications for its immunomodulatory drug, Ampion. The company is headquartered in Englewood, Colorado.
Latest AMPE News From Around the Web
Below are the latest news stories about Ampio Pharmaceuticals Inc that investors may wish to consider to help them evaluate AMPE as an investment opportunity.
Ampio Pharmaceuticals Presents Corporate Overview at H.C. Wainwright Bioconnect ConferenceAmpio Pharmaceuticals, Inc. (NYSE: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that it will present at the H.C. Wainwright Bioconnect Conference occurring virtually on January 10-13, 2022. Michael Martino, Chief Executive Officer, will present an updated corporate overview of Ampio and the presentation will be available on the event website beginning at 7:00 a.m. ET on January 10, 2022. |
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Cut to Hold at Zacks Investment ResearchZacks Investment Research lowered shares of Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) from a buy rating to a hold rating in a report issued on Thursday morning, Zacks.com reports. According to Zacks, Ampio Pharmaceuticals, Inc. develops proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. Principal products offered by the Company [] |
Ampio Pharmaceuticals CEO Mike Martino Issues Letter to StockholdersENGLEWOOD, Colo., Dec. 16, 2021 Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent Read More The post Ampio Pharmaceuticals CEO Mike Martino Issues Letter to Stockholders appeared first on Ampio Pharmaceuticals . |
Ampio Pharmaceuticals' CEO Mike Martino Issues Letter to StockholdersAmpio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today released the following letter to stockholders from its Chief Executive Officer, Mike Martino. |
Ampio (AMPE) Upgraded to Buy: Here's What You Should KnowAmpio (AMPE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
AMPE Price Returns
| 1-mo | -19.81% |
| 3-mo | -63.04% |
| 6-mo | -84.40% |
| 1-year | -90.61% |
| 3-year | -67.31% |
| 5-year | -77.63% |
| YTD | -70.18% |
| 2021 | -64.15% |
| 2020 | 172.73% |
| 2019 | 47.59% |
| 2018 | -90.29% |
| 2017 | 352.22% |
Loading social stream, please wait...